IDEAYA Biosciences Announces Clinical Collaboration with AstraZeneca to Evaluate IDE849 and Imfinzi in SCLC

On April 8, 2026, IDEAYA Biosciences announced a clinical collaboration agreement with AstraZeneca to evaluate the efficacy and safety of IDE849 in combination with AstraZeneca’s Imfinzi (durvalumab). IDE849 is IDEAYA’s potential first-in-class DLL3-targeted TOP1 antibody-drug conjugate (ADC). The combination study will specifically target patients with extensive-stage small cell lung cancer (SCLC). Under the terms of the agreement, IDEAYA will serve as the sponsor for the clinical combination study, while AstraZeneca will provide the supply of Imfinzi. IDEAYA is currently advancing a global Phase 1 clinical trial for IDE849 as a monotherapy and in combinations across various DLL3-upregulated solid tumors, including SCLC, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma. DLL3 is a promising therapeutic target due to its high expression in these cancers and limited presence in normal tissues. The study is expected to enroll patients across North America, Europe, Australia, South America, and Asia.